RE:What nextThere is no certainty about what might happen between now and the end of the year. We will get a phase 1b update at some point but that is less clear as to exactly when it will occur. Given the data shared at the cancer conference in Spain yesterday, TH should be seeing good info in phase 1b already but we do not have much clarity about how they are running the trial exactly and when they might report preliminary results, protocol amendments or PoC. Still, we can make some guesses about what the immediate future might hold for us:
1.) Truist took TH out to meet investors and was paid to help them with their debt deal. As a result, the possibility exists that Truist will produce a research report on THTX. If so, it would likely have a comprehensive analysis of TH's cancer opportunity.
2.) TH apparently met with some brokers who service primarily retail investors on one of their trips to New york. So, there is always a chance one or more retail brokers pick up coverage of the stock. It is hard to the quality of the report that might be written or its impact but as we saw with Zip Trader and, as so many other smaller cap stocks have experienced, retail interest in a stock can be very meaningful to the share price. The stock's reaction to such retail investor interest may not be congruant with reality but there is usually an reaction or even overreaction for a period of time.
3.) There are normally a lot of investor conferences at this time of year that TH can potentially paprticipate in. Since TH would likely want to raise additional funds via a share offering if they do have good cancer results, they are probably motivated to participate in any conferneces they can to prep institutional investors for what may be on the horizon with cancer and an offering. If they are on conference agendas' we may get a glimpse into the current state of the phase 1b and maybe some clarity as to when we can expect the next piece of meaningful news.
4.) The PR yesterday noted other preclinical work they are doing on other PDC's. They could announce something on that front at any time.
Hopefully, TH figures out ways to engage with investors in the next couple of months while we wait for important news on the phase 1b. While there is likely to be an analyst report or two, in the end, the most important development will be meaningful news on the phase 1b trial. If the news is good, the stock will jump because the analysts will start treating it like it is a real thing. If the news is bad, then the new PDC's they are working on will move to the forefront and a lot more waiting will be required.
Biobob wrote: So what now. What's the next exciting event for Th. Is it the possibility of P1b update between now and the end of Q1.